← Back to Search

Drug Therapy for Anxiety

N/A
Recruiting
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and females who are between 18 and 40 years of age
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up derived from eegs recorded for 30-45 mins
Awards & highlights

Study Summary

This trial will attempt to identify if there is a relationship between vestibular signals and anxiety by studying the effects of two different drugs known to reduce the theta rhythm.

Who is the study for?
This trial is for men and women aged 18-40 without a history of substance use disorders, neurological illnesses, major hearing loss, or severe allergies. They shouldn't be pregnant, left-handed, colorblind, have had psychological treatment or taken psychiatric drugs in the past year.Check my eligibility
What is being tested?
The study tests if non-invasive EVestG technology can detect anxiety by measuring hippocampal theta rhythms from the ear canal. Participants will receive Buspirone or Triazolam (both known to reduce theta rhythm) versus a placebo in a double-blind setup.See study design
What are the potential side effects?
Potential side effects include dizziness, nausea, headache from Buspirone; drowsiness, memory issues from Triazolam; and no active side effects expected from the placebo.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 40 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~derived from eegs recorded for 30-45 mins
This trial's timeline: 3 weeks for screening, Varies for treatment, and derived from eegs recorded for 30-45 mins for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
4-12 Hz modulation
EEG power spectrum
Secondary outcome measures
Signal correlations

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: TriazolamExperimental Treatment1 Intervention
Participants will receive triazolam 0.25 mg prior to experiments.
Group II: BuspironeExperimental Treatment1 Intervention
Participants will receive buspirone 10 mg prior to experiments.
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive a placebo prior to experiments.

Find a Location

Who is running the clinical trial?

University of ManitobaLead Sponsor
597 Previous Clinical Trials
199,430 Total Patients Enrolled
8 Trials studying Anxiety
562 Patients Enrolled for Anxiety

Media Library

Triazolam 0.25 MG Oral Tablet Clinical Trial Eligibility Overview. Trial Name: NCT03954483 — N/A
Anxiety Research Study Groups: Triazolam, Buspirone, Placebo
Anxiety Clinical Trial 2023: Triazolam 0.25 MG Oral Tablet Highlights & Side Effects. Trial Name: NCT03954483 — N/A
Triazolam 0.25 MG Oral Tablet 2023 Treatment Timeline for Medical Study. Trial Name: NCT03954483 — N/A
~27 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top